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Abstract
Regulatory T (Treg) cells control immune activation and maintain tolerance. How Tregs mediate their suppressive function is
unclear. Here we identified a cell surface molecule, called GARP, (or LRRC32), which within T cells is specifically expressed in
Tregs activated through the T cell receptor (TCR). Ectopic expression of GARP in human naı ¨ve T (TN) cells inhibited their
proliferation and cytokine secretion upon TCR activation. Remarkably, GARP over-expression in TN cells induced expression
of Treg master transcription factor Foxp3 and endowed them with a partial suppressive function. The extracellular but not
the cytoplasmic region of GARP, was necessary for these functions. Silencing Foxp3 in human Treg cells reduced expression
of GARP and attenuated their suppressive function. However, GARP function was not affected when Foxp3 was
downregulated in GARP-overexpressing cells, while silencing GARP in Foxp3-overexpressing cells reduced their suppressive
activity. These findings reveal a novel cell surface molecule-mediated regulatory mechanism, with implications for
modulating aberrant immune responses.
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Introduction
Regulatory T cells (Tregs) were recently identified as a
specialized subset of T cells that suppress auto-reactive cells to
maintain immunological tolerance and inhibit autoimmunity [1].
Tregs have also been shown to control excessive or chronic immune
activation after infections with various pathogens [2]. Naturally
occurring Tregs are thought to be generated in the thymus, express
high levels of CD25 and the transcription factor forkhead box
protein P3 (Foxp3), and constitute about 5–10% of periphery total
CD4
+ T cells in mice [1]. Human and murine Tregs share similar
characteristics, such as hypo-responsiveness to T cell receptor
(TCR) activation and mediation of their suppressive activity
through cell-contact-dependent mechanisms [1]. Foxp3 is critical
in Treg development and function. Mice that are deficient in
Foxp3 develop severe autoimmune diseases, and mutations of
human Foxp3 gene result in immunodysregulation, polyendocri-
nopathy, enteropathy, X linked syndrome (IPEX), which also is
characterized by severe autoimmunity [1,2].
Although the characteristics and function of Tregs have been
extensively studied, mechanisms of how Tregs mediate their
suppressive activity are still unclear. Various mechanisms have
been proposed, such as cytokine deprivation-induced apoptosis
[3], secretion of inhibitory cytokines [4,5], manipulation of antigen
presenting cells (APCs)[6], and recruitment of mast cells [7].
Several molecules have also been proposed to be important in Treg
generation, development or function, such as glucocorticoid-
induced TNF receptor (GITR)[8], indoleamine 2,3-dioxygenase
(IDO)[9], Heme oxygenase-1 (HO-1)[10], lymphocyte activation
gene-3 (LAG-3)[11]. How these diverse sets of molecules regulate
Treg cell differentiation and suppressive function remain unre-
solved.
In this report, we identified a Treg cell specific cell surface
molecule called GARP or LRRC32. Ectopic expression of GARP
in primary human T cells remarkably induced Foxp3 expression
and endowed them with partial Treg phenotype, including
impairment of proliferative capacity and acquisition of a
suppressive activity. Structure-function analysis of GARP revealed
that the extracellular domain, but not the cytoplasmic region, was
important for its function, suggesting an interaction of GARP with
other signaling receptor(s). Thus, determining the role of this novel
molecule in Treg mediated suppression could be important in
understanding tolerance mechanisms and exploiting its function
for regulating immune responses.
Results and Discussion
Identification of a cell surface molecule expressed on
activated Treg cells
In order to identify novel molecules that could be involved in
human Treg development and function, we first isolated human T
cell subsets as previously described [12]. The purified CD4
+ T cells
from healthy donors, were divided into four subsets based on
CD45RO and CD25 staining: 1) Tregs (CD45RO
+CD25
hi)2 )
Memory T (TM) cells (CD45RO
+CD25
2) 3) Naı ¨ve T (TN) cells
(CD45RO
2CD25
2) and 4) Naı ¨ve subset of Treg (TNreg) cells
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2CD25
hi)[12–15] as shown in Fig. 1A. The fourth
group of human T cell subset, TNreg cells, which was recently
characterized, displays an intermediate suppressive capacity ex vivo
but can be expanded in vitro to develop into fully mature Tregs [12–
15]. All four groups of purified T cell subsets were then stimulated
through the T cell receptor (TCR) overnight and RNA was
extracted for DNA gene chip analysis to identify Treg specific
genes. The DNA microarray analysis led to identification of a cell
surface molecule that was expressed more than 100 fold in both
TNreg and Tregs as compared to TN or TM cells (Fig. 1B). This 662
amino acid (aa) encoding gene, originally called GARP or LRRC32,
was found to be expressed at high levels in placenta, lung and
kidney [16,17].
To confirm the high expression level of GARP in activated
Tregs, we performed quantitative real time RT-PCR (qPCR)
analysis of GARP gene expression in all T cell subsets stimulated
through the TCR. Consistent with the microarray data, qPCR
also showed that the expression levels of GARP in both TNregs and
Tregs were more than 100 fold higher as compared to TN cells and
about 10 fold higher than TM cells (Fig. 1C).
Figure 1. GARP is specifically expressed in activated Treg cells. (A) Representative T cell subset staining from normal donor. CD4
+ T cells
isolated from human PBMC were stained with anti-CD25 and CD45RO antibodies. Naı ¨ve (TN), memory (TM), TNreg and Treg cells were identified as
shown in brackets. (B) GARP levels of recently activated T cell subsets from the microarray. (C) GARP levels of different T cell subsets 1 day post TCR
activation as determined by qPCR. One representative experiment of five donors is shown. (D) Kinetics of GARP levels in different T cell subsets at
different time points before and after TCR stimulation. Diamond, TN; square, TM; triangle, TNreg; cross, Treg. d, day. One experiment representative of
three donors is shown. (E) Expanded Treg cells from TNreg precursors and (F) Foxp3-transduced cells upregulate GARP after TCR stimulation. Cells were
in vitro expanded for two weeks before subjecting to qPCR analysis. Teff, expanded TN cells; Vector
+, control vector-transduced TN cells; Foxp3
+,
Foxp3-transduced TN cells. One experiment representative of three donors is shown.
doi:10.1371/journal.pone.0002705.g001
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cell subsets, qPCR analysis for GARP expression was performed in
TN,T M,T Nreg or Treg cells either at a resting state or at different
time points post-activation. We found that GARP is rapidly
upregulated after TCR stimulation in both TNregs and Tregs
(Fig. 1D). Interestingly, high level of GARP persisted for at least
5 days on Tregs, but declined in TNregs within 2 days. This could
be because TNregs are not fully mature and have to undergo a
differentiation program to sustain GARP expression [12].
However, post in vitro expansion, TNreg cells acquire complete
Treg characteristics both phenotypically and functionally [12].
Indeed, in vitro expanded TNregs (hereafter referred as Tregs) also
upregulated GARP expression post TCR activation and exhibited
kinetics of GARP expression that were similar to Tregs directly
isolated from peripheral blood (Fig. 1E and data not shown).
Furthermore, ectopic expression of Foxp3 in TN cells, which can
program them into Tregs [18] also upregulated GARP mRNA
expression (Fig. 1F and data not shown). Taken together these
findings suggest that GARP expression is specifically induced on
natural or reprogrammed Tregs upon TCR stimulation, and might
be involved in maintenance of Treg characteristics or Treg-
mediated suppressive activity.
Overexpression of GARP endows TN cells with partial Treg
phenotype and function
To explore the role of GARP in Treg development and function,
we subcloned human GARP into a HIV-derived vector (HDV)
that encodes red fluorescent protein (RFP) as a marker [18]. TN
cells were isolated as described above, activated by monocyte-
derived dendritic cells (DC) plus superantigen (SEB), and
transduced with HDV encoding GARP, Foxp3 or vector only as
control. Expression of GARP and Foxp3 in transduced cells was
confirmed by qPCR and intracellular staining respectively (data
not shown). The transduced cells were expanded in IL-2
containing media for two weeks, and stained for CD25 and
CD62L, which are known to be expressed at higher levels on
naturally occurring Tregs or on Foxp3-overexpressing T cells
[19,20]. GARP-transduced cells expressed higher levels of CD25
and CD62L than the control vector-transduced cells, but the
expression was lower compared to the Foxp3-transduced cells
(Fig. 2A). Remarkably, GARP-transduced cells expressed higher
level of Foxp3 compared to the cells transduced with the control
vector after re-activation with DCs pulsed with SEB (Fig. 2A).
To determine whether GARP-expressing T cells display
functional properties of Tregs, transduced cells were sorted on
the basis of RFP expression and stimulated through DCs pulsed
with SEB at suboptimal concentrations. Cytokine production in
the activation culture was assessed. T cells ectopically expressing
GARP secreted lower levels of IL-2 and IFNc compared to control
vector-transduced T cells (Fig. 2B). To assess the proliferative
capacity of GARP-expressing cells, transduced cells were labeled
with Carboxyfluorescein succinimidyl ester (CFSE) and stimulated
through TCR. GARP-expressing cells also displayed decreased
proliferative capacity as compared to the T cells expressing vector
Figure 2. Ectopic expression of GARP endows TN cells with partial Treg phenotype and function. (A) GARP-transduced cells express
higher levels of CD25 and CD62L, and upregulate Foxp3 at a greater level after TCR stimulation than the control vector-transduced cells. Cells were
transduced and expanded for two weeks before staining for CD25 and CD62L. RFP
+ cells were then sorted and re-stimulated by DC plus SEB at
suboptimal conditions before staining for Foxp3. Vector
+, control vector-transduced TN cells; GARP
+, GARP-transduced TN cells; Foxp3
+, Foxp3-
transduced TN cells. M, Geometric mean. Data are representative experiments from at least three different donors. (B) GARP-transduced cells produce
reduced levels of cytokines. Cytokine production in the supernatant of the activation culture was measured using CBA and data are shown by first
normalizing the control geometric mean to be 100%. Range of control production (pg/ml): IL-2, 300–1000; IFNc, 3000–10000. Data represent the
mean6SEM of experiments from at least three different donors. *, P,0.05, n$3; experimental versus control. (C) GARP-transduced cells exhibited
impaired proliferative capacity and (D) intermediate suppressive activity. Data are representative experiments from at least three different healthy
human donors.
doi:10.1371/journal.pone.0002705.g002
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Furthermore, GARP-expressing cells displayed some suppressive
activity against TN targets, although this was not as potent as
Foxp3-transduced cells (Fig. 2D). Taken together, our data
indicate that T cells ectopically expressing GARP acquire a
partial phenotypic and functional profile of Tregs.
GARP function requires the extracellular region but not
the cytoplasmic portion
The GARP gene encodes a cell surface protein with a signal
peptide (SP) for cell surface translocation [21], an extracellular
region that is composed of 20 leucine-rich repeats (LRRs), a
transmembrane domain (TM) and a short cytoplasmic region of
15 aa [17,22]. LRR domains in other proteins are involved in a
variety of functions, principally through protein-protein interac-
tion [23]. Because GARP has a very short cytoplasmic region, we
hypothesized that only the extracellular LRRs and the SP are
required for its function. Accordingly, we prepared three different
mutants: 1) Deletion of the cytoplasmic tail (DC), 2) Deletion of all
LRRs in the N-terminus (DN), and 3) Deletion of the SP at the N-
terminus (DSP). These mutants are shown schematically in Fig. 3A.
All mutants were sequence confirmed and subcloned into the
HDV, and lentiviral vectors were generated to transduce primary
TN cells. Phenotypic analysis revealed that TN cells expressing the
DC mutant showed similar upregulation of CD25, CD62L and
Foxp3 expression compared to the WT GARP, whereas T cells
expressing the DNo rDSP GARP mutants had lost this activity
(Fig. 3B and 3C).
Next, we compared proliferative capacity, cytokine production
and suppressive activity of the mutants to the WT GARP. Similar
to the surface phenotype, TN cells transduced with the DC mutant
exhibited impaired proliferative capacity, reduced cytokine
production, and enhanced suppressive capacity comparable to
WT GARP-expressing cells (Fig. 3D–F). However, the DN and
DSP mutant-expressing cells did not display any of the inhibitory
functions of GARP-expressing cells (Fig. 3D–F). Together, these
data indicate that both the SP and the LRRs in the extracellular
portion of GARP, but not the cytoplasmic domain, are crucial to
its function.
Does GARP mediate its inhibitory function through
expression of Foxp3?
We have shown that GARP was upregulated in freshly isolated
TNreg,T reg and Foxp3-expressing cells as well as in vitro expanded
Tregs (Fig. 1). These findings suggest that GARP is a potential
downstream effector molecule in Tregs. However, T cells ectopically
expressing GARP also upregulate Foxp3 expression in a sizeable
portion of these cells (Fig. 2A). Therefore, it is possible that
functional and phenotypic changes observed upon GARP overex-
pression could be indirectly due to induction of Foxp3, which then
induces other effector molecules. To address this possibility we
performed an experiment to silence Foxp3 expression in GARP-
transduced cells using shRNA against Foxp3. Cells were then
expanded for two weeks and efficient knockdown of Foxp3
expression was confirmed (Fig. 4A). As shown in Fig. 4B, silencing
Foxp3 in GARP-expressing cells did not alter their suppressive
ability,whiledownregulationofFoxp3inTregsresultedinsignificant
attenuation of their suppressive capability [12], which was reduced
to similar levels as GARP-expressing cells (Fig. 4B). Moreover,
GARP-expressing cells produced reduced levels of cytokines even in
the presence of Foxp3 shRNA (Fig. 4C), which was similar to
control shRNA expressing cells (data not shown). In addition,
silencing Foxp3 expression in Treg cells reduced induction of GARP
upon TCR activation (Fig. 4D), which correlated with partial loss of
suppressive activity in these cells (Fig. 4B). These findings suggest
that induction of GARP in Tregs is dependent on Foxp3 expression,
while its inhibitory action on T cell activation is independent of
sustained expression of Foxp3.
Silencing GARP in Foxp3-induced Treg cells attenuate
their suppressive activity
Induction of GARP expression requires the expression of Foxp3
while it can mediate its function independent of Foxp3 expression.
Based on these findings we hypothesize that GARP is an effector
molecule of suppression downstream of Foxp3 expression. To test
this hypothesis further, we silenced GARP expression through
shRNA in Foxp3-induced Tregs. We designed two different
shRNAs against GARP, which reduced the expression of GARP
between 60 to 80% in Foxp3-induced Tregs (data not shown). We
found that expression of GARP-shRNA in Foxp3-induced Tregs
attenuated their suppressive activity as compared to the control
shRNA expressing cells (Fig. 5). This important result supports our
hypothesis that a sizeable part of suppressive activity mediated by
Foxp3 is through the induction of GARP in Treg cells.
Discussion
Naturally occurring Tregs are crucial to the establishment of
immunological tolerance. Despite intense research, the mecha-
nisms by which Tregs mediate their suppressive effect are not
completely understood. Here we identified a molecule, called
GARP, which mediates part of the Treg suppressive activity.
Ectopic expression of GARP in human TN cells resulted in a
partial Treg phenotype, as determined by increased Foxp3, CD25
and CD62L expression, decreased cytokine production (IFNc and
IL-2), impaired proliferative capacity and display of suppressive
activity. Silencing GARP in Foxp3-induced Tregs reduced their
suppressive function. These data suggest a pivotal role for GARP
in controlling aberrant or unwanted T cell activation.
GARP is highly conserved across species, suggesting that it
mediates an important function [24]. The mouse and human
GARP amino acid sequences share 82% identity. The similarity
rises to 87% if conservative amino acid changes are allowed, which
argues the possibility for cross-reaction between mouse GARP
with human GARP binding partners. Indeed, similar to the
human counterpart, murine GARP was also upregulated only in
mature murine Tregs upon activation (Figure S1). Further, murine
GARP-expressing human T cells exhibited a very similar
phenotype as those expressing human GARP (Figure S1 C–F).
We conclude that both murine and human GARP are able to
interact with the human GARP binding partners. Future genetic
manipulation in mice to determine the role of GARP in vivo will be
invaluable in understanding the role of this molecule in function
and development of Treg cells.
GARP gene, originally called GARP, contains two exons. The
first exon encodes the signal peptide and nine amino acid residues,
and the second one contains 20 repeats of the LRR motif, the
transmembrane domain and a short cytoplasmic domain [17,24].
We found that deletion of LRRs in GARP results in complete loss
of its function, while mutant lacking the short cytoplasmic domain
behaved similarly to the WT GARP. The LRRs are generally 20–
29 residues long, with the consensus sequence LxxLxLxxN/CxL.
Proteins with LRR constitute a large superfamily involved in
diverse functions, such as adenylate cyclase in yeast, the
proteoglycans decorin and biglycan in human, and disease
resistance genes in plants [23]. GARP, as an LRR containing
molecule (LRRC32), shows similarity to glycoprotein V, which is
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PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2705Figure 3. Phenotypic and functional analysis of T cells ectopically expressing GARP mutants. (A) Schematic of WT and mutant GARPs. SP,
signal peptide; LRR, leucine-rich repeat; TM, transmembrane domain. (B) Both DN and DSP mutant-transduced cells do not sustain high levels of
CD25 and CD62L expression and (C) Foxp3 expression post-activation as determined by staining. Cells were transduced and prepared as described in
Fig. 2. M, Geometric mean. (D) Cytokine profiles of WT and mutant GARP-transduced cells. Cytokine production in the supernatant of the activation
culture was measured using CBA kit (BD Biosciences) and percent secretion in Y-axis is calculated by first normalizing the secretion of cytokines from
control cells to 100%, and calculating the amount of cytokine secreted from other cell conditions relative to this control. This representation allowed
us to combine data from multiple donors in the same figure. This normalization Data represent the mean6SEM of experiments from at least three
different donors. *, P,0.05; experimental versus control. Range of production (pg/ml): IL-2, 0–1000; IFNc, 0–10000. (E) Proliferative capacity is shown
as percentage of proliferated cells as determined by dilution of CFSE 4 or 5 days post re-stimulation. (F) Percentage of suppression was calculated
based on CFSE dilution of target TN cells in the suppression culture. The % suppression on Y-axis is calculated as follows: We first determined the
percent of CFSE labeled target cells dividing in response to the stimuli alone. We then determined the proliferative percentage of cells in the
presence of suppressor (Tregs or GARP expressing cells) or control effector T cells. The percent suppression was then calculated by percent reduction
in proliferation of the target cells in the presence of effectors as compared to target cells alone. As an example, in one experiment 40% of the CFSE
labeled T cells divided in response to SEB stimulation. In the presence of Tregs the same cells divided only 4%. Thus, we represent this as 90%
suppression. Data represent the mean6SEM of experiments from at least three different donors. * P,0.05; experimental versus control.
doi:10.1371/journal.pone.0002705.g003
A Molecule which Induces Foxp3
PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2705one of the components forming the GPIb-IX-V complex on
platelet surface famous for the interaction with von Willebrand
factor complex to mediate the adhesion of platelets to injured
vascular surfaces [25]. It was recently shown that GARP is
expressed on the cell surface of platelets using a polyclonal
antibody raised against its extracellular portion [22]. In addition,
we generated GFP-tagged versions of WT and DSP mutant of
GARP and based on image analysis of cells expressing a GFP,
confirmed WT but not DSP, appears to be localized to cell surface
region (Figure S2). This expression profile of GARP suggests that
LRRs at the extracellular region could mediate its function,
possibly through interaction with another cell surface molecule(s).
We also ruled out that GARP-mediated suppression is mediated
by a soluble factor since neither separating GARP-expressing cells
via transwells nor adding supernatants from these cells to target
cells showed any suppressive function (data not shown). Our
finding that the cytoplasmic region was dispensable also strongly
argues the possibility that GARP itself is not likely to be delivering
intracellular signals but conceivably may interact with a receptor
molecule expressed by target T cells, which deliver inhibitory
signals. Alternatively, GARP may be part of a signaling surface
complex similar to glycoprotein V [25].
We found that GARP was induced in T cells ectopically
expressing Foxp3 and reduced in expression when Foxp3 was
silenced in natural Tregs. These findings suggest that Foxp3 is a
regulator of GARP expression. It remains to be determined
whether Foxp3 directly activates GARP transcription or indirectly
through other transcription factors. It will also be interesting to
determine whether in IPEX patients or scurfy mice, which have
defective expression or mutations in Foxp3, GARP expression is
also reduced. Although Foxp3 appears to be required for GARP
expression in T cells, silencing Foxp3 in cells forced to express
GARP does not reduce their suppressive function. Furthermore,
we showed that silencing of GARP in Foxp3-induced Tregs
diminished their suppressive function. Together these data imply
that GARP is an effector molecule downstream of Foxp3 that can
directly display inhibitory signaling once it is expressed.
Peripheral tolerance to self-antigens is an important secondary
mechanism that prevents autoimmune reactions [26]. In addition,
Tregs have also been proposed to play a role in pregnancy by
allowing continuous release of placental antigens into the maternal
circulation, thus permitting tolerance towards the semiallogeneic
fetus until birth [9,27]. Previous studies postulated cellular
pathways affected by Treg action including production of
Figure 4. GARP functions as a downstream effector molecule of Foxp3 expression. (A) Efficient knockdown of Foxp3 expression in GARP-
transduced and Treg cells. TN cells were co-infected with shRNA-expressing HDV (GFP) and control or GARP-expressing HDV (RFP), while Tregs from the
same donor were transduced with shRNA-expressing HDV. Cells were cultured for two weeks before staining for CD25 and CD62L, and before sorting
for experimental lines: GFP
+RFP
+ for control vector or GARP-expressing cells; GFP
+ for Tregs. Foxp3 was stained after re-stimulation by DC and SEB.
Vector
+, control vector-transduced TN cells; GARP
+, GARP-transduced TN cells; Teff, expanded TN cells. (B) Suppressive activity and (C) cytokine profiles
of Foxp3 shRNA-expressing GARP-transduced and in vitro expanded Treg cells. Data represent the mean6SEM of experiments from three different
donors. Cytokine data are shown by first normalizing the control to be 100%. Range of control production (pg/ml): IL-2, 300–1000; IFNc, 3000–10000.
*, P,0.05, n$3; experimental versus control. (D) GARP level in in vitro expanded Treg cells was decreased by silencing Foxp3 as determined by qPCR
analysis day 2 or day 4 post TCR stimulation. d, day. Two different shRNA oligos against Foxp3 were tested, both of which have been described before
[12].
doi:10.1371/journal.pone.0002705.g004
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induction [9]. Interestingly, GARP was found to be highly
expressed in placenta in both mouse and human [17,24].
Expression of GARP in placenta might be essential in creating a
‘‘tolerant’’ privileged microenvironment to avoid rejection of the
fetus, and this privilege could even be independent of Tregs,
although it remains to be determined whether GARP expression
on non-T cells can also inhibit T cell activation.
In summary, GARP is highly specific to activated Treg cells, and
has the ability to mediate partial Treg characteristics, importantly
including their suppressive function. Identification of this Treg cell
specific molecule may have implications in understanding
regulation of unwanted immune responses and sustaining
tolerance by Treg cells. The discovery of GARP as an immune
suppressive molecule in primary human T cells may also be
relevant for exploiting the function of this molecule to modulate
immune responses during autoimmunity, transplantation or
persistent immune activation caused by chronic infections such
as HIV. Conversely, blocking GARP signals can amplify immune
responses to antigens in the context of vaccine development or
boost the immune response to infections and tumors.
Materials and Methods
Cell purification and culture
TN,T M,T Nreg and Treg cells, were purified and cultured as
described before [12,18]. Monocyte-derived dendritic cells (DCs)
were generated from CD14
+ cells from healthy donors as
previously described [18]. The superantigen, staphylococcal
enterotoxin B (SEB) was purchased from Sigma (St. Louis, MO).
The cytokines used were from R&D Systems (Minneapolis, MN).
Microarray gene analysis
10
6 T cells from each subset (TN,T M,T Nreg and Treg) were
activated by plate-bound anti-CD3 antibody (OKT-3; American
Type Culture Collection, Manassas, VA) and soluble anti-CD28
antibody (1 mg/ml, BD Biosciences, San Diego, CA) for 16 hours.
RNA was extracted from flash frozen cells and subjected to Agilent
whole Genome 4644K arrays at a commercial service (Genus
Biosystems, Northbrook, IL).
qPCR
Total RNA was isolated and cDNA was synthesized as
described before [18]. The cDNA was then used to perform
qPCR using a Stratagene Mx3005P (La Jolla, CA) or Applied
Biosystems 7300 apparatus (Foster City, CA). TaqMan primer and
probe mixes were purchased from Applied Biosystems, and their
IDs are as follows: b2actin (used as a reference gene):
Hs99999903_ml; GARP: Hs00194136_m1.
Cloning of GARP gene and construction of mutants
Full length human GARP cDNA (LRRC32) was purchased
from Origene (Rockville, MD) and amplified using the primers:
59forward: cacctctagagccatgagaccccagat;
39reverse: cccgggcttctttaggctttata.
To construct C-terminus truncated mutant (DC), the following
primers were used:
59forward: cacctctagagccatgagaccccagat;
39reverse: CCCGGGTTAGCAGGCGGCCAGCG-
TGGT.
The amplified DNA was then cloned into pENTR/D-TOPOH
vector system (Invitrogen). The N-terminus mutant (DN) was
cloned through PCR from WT GARP TOPO construct using the
following primer sets
59forward: gAGTactcagctgctgcggc;
39reverse: GAGTACTGGCGGGAGCACCGAGG.
The PCR product was ligated to construct the DN mutant. WT
GARP and the mutants were then subcloned into a HIV-derived
HDV expressing RFP (Clontech Laboratories, Mountain View,
CA) as marker gene as described [18]. To construct signal peptide
deleted mutant (DSP), the following primers were used:
59forward: GCTCTAGAGCATGGTGGACAA-
GAAGGTCTCGTGC;
39reverse: CCCGGGTTAGCAGGCGGCCAGCGT-
GGT.
To amplify murine GARP from cDNA library, the following
primers were used:
59forward: AGCGGCCGCATTATGAGCCACCA-
GATCCTGCTA;
39reverse: GGAATTCTCA GGCTTTGTATT-
GTTGGCTGAG.
The PCR product of murine GARP and DSP mutant was then
subcloned into the HDV. All constructs were sequence confirmed.
Lentiviruses expressing GARP or other genes used here were
generated as previously described [18].
Silencing of Foxp3 and GARP expression in primary T
cells
Foxp3 or GARP shRNA-expressing lentiviral vectors with GFP
as a marker was generated as previously described [12]. Two
different Foxp3 shRNA sequence were tested and both showed
efficient knock down of Foxp3 [12]. Both were used in
experiments presented here with representatives of both (Fig. 4D)
Figure 5. Silencing GARP in Foxp3-induced Tregs attenuate
their suppressive activity. CD4+ T cells were co-transduced with
shRNA-expressing or control lentiviruses (GFP+) and Foxp3-expressing
lentiviral vectors (RFP+). GFP+ RFP+ T cells expressing both shRNA for
GARP and Foxp3, were first sorted to high purity through FACS. The
suppressive activity of these cells were then determined using CFSE
assay and represented as percent suppression as described in detail in
Figure 3. Data are representative experiments from two different
donors and shows independent results from two separate shRNAs
against GARP. Data represent the mean6SEM.
doi:10.1371/journal.pone.0002705.g005
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were : sh1: GGAATTCCCTCACCTGCATCT; sh2: GGAGAA-
CAAACTGCTCCATTT.
FACS analysis
Cells were stained, analyzed as described before [12]. The
following antibodies were used for staining: CD45RO, CD25
(both from BD Biosciences), CD62L (eBioscience, San Diego, CA).
Foxp3 expression was performed with anti-Foxp3 antibody (clone
259D; Biolegend, San Diego, CA) through intracellular staining as
described before [12].
Cell proliferation, suppression and cytokine assays
Cells were labeled with CFSE (Molecular Probes, Eugene, OR)
as previously described [18] and activated by DC and SEB at
different concentrations. Supernatant from the culture were
collected 16–40 hours later. Suppression assays were set up as
previously described [12]. Cytokine production was measured
using cytometric bead array (CBA; BD Biosciences) and analyzed
by FlowJo (Tree Star, Ashland, OR). Data represent the
mean6SEM of experiments from at least three different donors.
Proliferation of the cells was assessed by monitoring expression
CFSE on day 4 or day 5 post-activation.
Detection of GARP by fluorescence microscope
WT GARP was PCR amplified with following primers:
59forward: cacctctagagccatgagaccccagat;
39reverse: TGGCTTTATACTGTTGG.
DSP mutant GARP was PCRed using primers:
59forward: GCTCTAGAGCATGGTGGACAA-
GAAGGTCTCGTGC;
39reverse: TGGCTTTATACTGTTGG.
The PCR products were ligated in pcDNA3.1/CT-GFP-
TOPOH vector system (Invitrogen). Both constructs were transfect-
ed into 293T cells by lipofectamine 2000 (Invitrogen) following the
manufacture’s instructions. pcDNA3.1 GFP was used as control.
24 hourspost transfection, cellswerewashed with cold PBS,fixedat
4uC in 4% paraformaldehyde for 10 min, washed one more time
with PBS and mounted on glass coverslips in Aqua Poly/Mount
(Polysciences, Inc, Warrigton, PA). Samples were visualized by
Zeiss, Axiover 200 fluorescence microscope (Bernried, Germany),
recorded by QImaging Retiga EX digital camera (Minneapolis,
MN)andanalyzed byOpenlab 3.1.7 (Improvision,Lexington,MA).
Nuclei were stained with Hoechst 33342 (Invitrogen).
Detection of mouse GARP in murine T cell subsets
CD4
+CD25
2 and CD4
+CD25
+ T cells were purified from
spleen of C57BL/6 mice by FACS. Sorted cells were stimulated
with anti-CD3 and anti-CD28 antibodies (2 mg/ml each) for
24 hours. CD4
2CD8
2 (double negative, DN), CD4
+CD8
+
(double positive, DP), CD4 single positive (SP) and CD8 SP cells
were purified from thymus of C57BL/6 mice by FACS. mRNA
were purified and subjected to cDNA synthesis. Primers used for
detection of mouse GARP are:
59forward: TGAATTCATGAGCCACCAGATCCTG-
CTACTC;
39reverse: AGCGGCCGCTCAGGCTTTGTATTG-
TTGGCTGAG.
Primers for detection of mouse G3PDH (glyceraldehyde-3-
phosphate dehydrogenase) are described previously [28].
Statistical Analysis
The significance was determined using One-Sample Student’s t-
test or One-way ANOVA.
Supporting Information
Figure S1 Murine GARP is functionally similar to human
counterpart. A) Murine GARP (mGARP) expression in mouse T
cell subsets. mGARP expression in different T cell subsets and
developing stages in mice as determined by semi-quantitative
PCR. DN, double negative; DP, double positive; SP, single
positive. G3PDH was used as loading control. One representative
experiment of three is shown. (B) mGARP-transduced human TN
cells displayed high levels of CD25 and CD62L expression and (C)
Foxp3 expression post-activation. Cells were transduced and
prepared as described in Fig. 2. M, Geometric mean. (D) Cytokine
profiles of mGARP-transduced cells. Data are shown by first
normalizing the control to be 100% and represent the mean6
SEM of experiments from at least three different donors. Range of
control production (pg/ml): IL-2, 300–1000; IFNc, 3000–10000.
*, P,0.05, n=3; experimental versus control. (E) mGARP-
transduced cells exhibited impaired proliferative capacity and (F)
intermediate suppressive activity. Data are representative exper-
iments from at least three different donors.
Found at: doi:10.1371/journal.pone.0002705.s001 (0.14 MB TIF)
Figure S2 Localization of WT GARP but not DSP mutant to
cell surface. Control GFP, WT GARP-GFP and DSP mutant
GARP-GFP fusion protein expression in transfected 293T cells.
Green, GFP; blue, Dapi. Shown are two representative merged
images for WT and DSP mutant expressing cells.
Found at: doi:10.1371/journal.pone.0002705.s002 (0.17 MB
PDF)
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